[go: up one dir, main page]

BR112018069789A2 - medicamento obtido pela combinação do agonista de fxr e arb - Google Patents

medicamento obtido pela combinação do agonista de fxr e arb

Info

Publication number
BR112018069789A2
BR112018069789A2 BR112018069789A BR112018069789A BR112018069789A2 BR 112018069789 A2 BR112018069789 A2 BR 112018069789A2 BR 112018069789 A BR112018069789 A BR 112018069789A BR 112018069789 A BR112018069789 A BR 112018069789A BR 112018069789 A2 BR112018069789 A2 BR 112018069789A2
Authority
BR
Brazil
Prior art keywords
arb
fxr
agonist
combining
medicine obtained
Prior art date
Application number
BR112018069789A
Other languages
English (en)
Inventor
Yoshiji Hitoshi
Namisaki Tadashi
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of BR112018069789A2 publication Critical patent/BR112018069789A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a um agente terapêutico nash incluindo: um agonista de fxr, de preferência, ácido obeticólico ou um seu sal farmaceuticamente aceitável; e um arb ou um sal farmaceuticamente aceitável do mesmo.
BR112018069789A 2016-03-28 2017-03-27 medicamento obtido pela combinação do agonista de fxr e arb BR112018069789A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064475 2016-03-28
PCT/JP2017/012448 WO2017170434A1 (ja) 2016-03-28 2017-03-27 Ｆｘｒアゴニストとａｒｂの組み合わせ医薬

Publications (1)

Publication Number Publication Date
BR112018069789A2 true BR112018069789A2 (pt) 2019-01-29

Family

ID=59965591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069789A BR112018069789A2 (pt) 2016-03-28 2017-03-27 medicamento obtido pela combinação do agonista de fxr e arb

Country Status (17)

Country Link
US (1) US11419878B2 (pt)
EP (1) EP3437659B1 (pt)
JP (1) JPWO2017170434A1 (pt)
KR (1) KR20180124123A (pt)
CN (1) CN109152840A (pt)
AU (1) AU2017241559A1 (pt)
BR (1) BR112018069789A2 (pt)
CA (1) CA3019496A1 (pt)
CL (1) CL2018002727A1 (pt)
EA (1) EA037330B1 (pt)
IL (1) IL262057A (pt)
MX (1) MX2018011813A (pt)
PH (1) PH12018502109A1 (pt)
SG (1) SG11201808607SA (pt)
TW (1) TW201733582A (pt)
UA (1) UA124499C2 (pt)
WO (1) WO2017170434A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112771026A (zh) * 2018-08-30 2021-05-07 拓臻制药公司 治疗肝脏病症
BR112021008015A2 (pt) * 2018-11-08 2021-08-03 Intercept Pharmaceuticals, Inc. métodos de uso de ácido obeticólico
DE102019108825A1 (de) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbindungen und Verfahren zur Behandlung von Erkrankungen der Leber
KR20210020788A (ko) 2019-08-14 2021-02-24 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
AU2020380968A1 (en) * 2019-11-08 2022-05-12 Terns Pharmaceuticals, Inc. Treating liver disorders
WO2021133948A1 (en) * 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
JP2023525570A (ja) * 2020-05-13 2023-06-16 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の併用処置
WO2022046779A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR20230066399A (ko) * 2020-09-11 2023-05-15 테른스 파마슈티칼스, 인크. Fxr 작용제의 고형 분산물 제제
KR20230043773A (ko) 2021-09-24 2023-03-31 (주)샤페론 염증복합체 억제제를 유효성분으로 함유하는, 비알코올성 지방간염, 간 섬유화의 예방, 개선 또는 치료용 약학적 조성물
KR20230052237A (ko) 2021-10-12 2023-04-19 (주)샤페론 타우로데옥시콜산 신규 제제
EP4467156A1 (en) * 2022-01-21 2024-11-27 Nagasaki University Pharmaceutical composition for suppressing organ fibrosis
KR20240099045A (ko) * 2022-12-20 2024-06-28 주식회사 티에치팜 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
CN117838692A (zh) * 2023-11-17 2024-04-09 上海交通大学医学院附属新华医院 NR1H4激动剂Tropifexor在小儿短肠综合征肠道代偿治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
HUE024952T2 (en) * 2004-03-12 2016-02-29 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
JP5222846B2 (ja) 2006-06-27 2013-06-26 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介疾患または状態の予防または治療のためのｆｘｒリガンドとしての胆汁酸誘導体
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
KR20150022974A (ko) * 2012-06-19 2015-03-04 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태
EP3409279A1 (en) * 2013-03-15 2018-12-05 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
KR20150127599A (ko) * 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
US20160151486A1 (en) 2013-06-13 2016-06-02 Fast Foward Pharmaceuticals B.V. CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis
JPWO2015008849A1 (ja) 2013-07-18 2017-03-02 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途

Also Published As

Publication number Publication date
TW201733582A (zh) 2017-10-01
JPWO2017170434A1 (ja) 2019-01-31
EP3437659A1 (en) 2019-02-06
PH12018502109A1 (en) 2019-09-23
AU2017241559A1 (en) 2018-11-01
MX2018011813A (es) 2019-01-24
EP3437659A4 (en) 2019-12-11
EA201892119A1 (ru) 2019-02-28
IL262057A (en) 2018-11-29
EA037330B1 (ru) 2021-03-12
KR20180124123A (ko) 2018-11-20
CN109152840A (zh) 2019-01-04
WO2017170434A1 (ja) 2017-10-05
SG11201808607SA (en) 2018-11-29
CA3019496A1 (en) 2017-10-05
US11419878B2 (en) 2022-08-23
US20190247404A1 (en) 2019-08-15
UA124499C2 (uk) 2021-09-29
CL2018002727A1 (es) 2018-12-07
EP3437659B1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
EA201790398A1 (ru) Способы лечения заболевания печени
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
PH12017500493A1 (en) Combination therapy
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
BR112017000556A2 (pt) terapia de combinação para câncer
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX389336B (es) Formulacion farmaceutica.
EA201691231A1 (ru) Фармацевтические лекарственные формы
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112019000509A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements